ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$61.65
+3.56%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$61.75
From 52W high−31.19%
Volume1.47M
Market cap$8.71B
P/E (TTM)—
P/S (TTM)13.0x
Div yield—
Key dataNov 4, 2026
Open
$61.75
From 52W high
−31.19%
Volume
1.47M
Market cap
$8.71B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−59.6x
P/E (TTM)
—
RSI (14)
45.5
MomentumView details →
1D Return
+3.56%
YTD Return
−8.40%
SummaryUpdated Jun 1, 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a clinical-stage biotechnology company founded in 1989 and headquartered in Pasadena, California. The company went public in 1993 and has evolved into a leading developer of RNA interference (RNAi) therapeutics for treating rare and complex diseases. Arrowhead has built a proprietary platform technology that enables targeted delivery of RNAi medicines to specific tissues and organs, with a robust pipeline spanning multiple therapeutic areas including cardiometabolic diseases, pulmonary disorders, muscular dystrophy, and central nervous system conditions.
Similar companies
Latest newsMore news →
ARROWHEAD PHARMACEUTICALS, INC. completed a refinancing with funds managed by Sixth Street LLC, retiring its existing $400 million facility at a $68 million discount to the contractual minimum repayment amount and establishing a new $400 million facility.10h agoARROWHEAD PHARMACEUTICALS, INC. announced that it will present clinical data at the American Heart Association, Inc. Scientific Sessions in Chicago on November 7, 2026.2d ago